Sign in

    Junwoo Park

    Vice President and Equity Research Analyst at Cantor Fitzgerald

    Junwoo Park is a Vice President and Equity Research Analyst at Cantor Fitzgerald, specializing in coverage of the biopharmaceutical and biotechnology sectors. He covers a portfolio of innovative companies such as Immunovant, Apellis Pharmaceuticals, and Apogee Therapeutics, and his research is noted for in-depth clinical trial analysis and sector insights. Park began his career in healthcare investment banking, holding roles at Guggenheim Securities and Bloomberg LP before joining Cantor Fitzgerald in 2022. He holds FINRA Series 7 and 63 licenses and is recognized by clients for the analytical rigor and objectivity he brings to equity research.

    Junwoo Park's questions to Sanara MedTech (SMTI) leadership

    Junwoo Park's questions to Sanara MedTech (SMTI) leadership • Q1 2025

    Question

    Junwoo Park, on for Ross Osborn, asked for guidance on gross margin cadence for the remainder of 2025 and inquired about the success metrics for the Tissue Health Plus pilot program.

    Answer

    Executive Ronald Nixon addressed gross margins, noting a recent benefit from a technology acquisition but advising to model margins consistent with the past, as significant further leverage is not expected. Executive Suresh Muppalla detailed the three categories of success metrics for the pilot: clinician-facing (protocol adherence), operational (staff productivity, cost reduction), and adoption (user satisfaction surveys).

    Ask Fintool Equity Research AI

    Junwoo Park's questions to PAVmed (PAVM) leadership

    Junwoo Park's questions to PAVmed (PAVM) leadership • Q4 2024

    Question

    Junwoo Park, on for Ross Osborn, asked for an update on discussions with other institutions for Veris pilot programs, key learnings from the Ohio State University pilot, and the potential FDA approval pathway for the PortIO device.

    Answer

    Dr. Lishan Aklog, Chairman and CEO, stated that while discussions are ongoing with about a dozen other cancer centers, Veris is currently focusing resources on the OSU engagement and advancing the implantable device before a broader expansion. For PortIO, he outlined a straightforward de novo regulatory path requiring an IDE study of 50-80 patients, with a goal for FDA clearance within two years of the study's launch, pending financing.

    Ask Fintool Equity Research AI

    Junwoo Park's questions to NeuroPace (NPCE) leadership

    Junwoo Park's questions to NeuroPace (NPCE) leadership • Q4 2024

    Question

    Matthew Park, on for Ross Osborn at Cantor Fitzgerald, asked about the site of service dynamics for the potential pediatric indication, questioning if procedures would be concentrated in Level 4 centers or see broader adoption. He also inquired about NeuroPace's manufacturing capacity for 2026 and beyond given the expanding market opportunity.

    Answer

    Executive Joel Becker explained that the site of service for pediatric patients would be determined by epilepsy type, not age. Focal epilepsy patients requiring Phase II monitoring would likely be treated in Level 4 centers, while generalized epilepsy patients could be treated in Level 3 or community centers. Regarding manufacturing, he stated concisely that NeuroPace is in 'good shape from a capacity perspective' and is 'ready to go.'

    Ask Fintool Equity Research AI

    Junwoo Park's questions to CERUS (CERS) leadership

    Junwoo Park's questions to CERUS (CERS) leadership • Q3 2024

    Question

    Junwoo Park of Roth MKM inquired about the need for additional manufacturing capacity for the INTERCEPT Fibrinogen Complex (IFC) following new BLA approvals and the approval and replacement timeline for the new LED illuminator.

    Answer

    COO Vivek Jayaraman stated that Cerus will continue to add manufacturing partners to meet growing IFC demand. President and CEO Obi Greenman added that the LED illuminator is targeted for a 2025 European launch, with a U.S. submission likely in the 2026 timeframe, serving as a new foundational platform for the business.

    Ask Fintool Equity Research AI